Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Drug Resistance, Microbial.
Connection Strength

0.633
  1. Relevant aspects in the Infectious Diseases Society of America (IDSA) guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Int J Hematol. 1998 Oct; 68 Suppl 1:S31-4.
    View in: PubMed
    Score: 0.151
  2. Paul Ehrlich, a prescient pioneer in the field of antimicrobial chemotherapy: what did he foresee a century ago? Expert Rev Anti Infect Ther. 2013 Feb; 11(2):113-5.
    View in: PubMed
    Score: 0.102
  3. Antibiotic use: present and future. New Microbiol. 2007 Jul; 30(3):321-5.
    View in: PubMed
    Score: 0.069
  4. The search for new antimicrobials: why we need new options. Expert Rev Anti Infect Ther. 2005 Dec; 3(6):907-13.
    View in: PubMed
    Score: 0.062
  5. New pathogens in neutropenic patients with cancer: an update for the new millennium. Int J Antimicrob Agents. 2000 Oct; 16(2):97-101.
    View in: PubMed
    Score: 0.043
  6. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis. 1999 Sep; 29(3):490-4.
    View in: PubMed
    Score: 0.040
  7. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection. Antimicrob Agents Chemother. 1998 Jan; 42(1):72-7.
    View in: PubMed
    Score: 0.036
  8. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis. 1991 Sep; 164(3):499-506.
    View in: PubMed
    Score: 0.023
  9. Single daily dosing of amikacin in an in-vitro model. J Antimicrob Chemother. 1991 May; 27 Suppl C:15-9.
    View in: PubMed
    Score: 0.023
  10. Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones. J Antimicrob Chemother. 1990 Jun; 25(6):941-8.
    View in: PubMed
    Score: 0.021
  11. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987 Jul; 31(7):1054-60.
    View in: PubMed
    Score: 0.017
  12. Bacterial pathogens of increasing significance in hospital-acquired infections. Rev Infect Dis. 1985 Jul-Aug; 7 Suppl 3:S371-9.
    View in: PubMed
    Score: 0.015
  13. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother. 1985 Mar; 27(3):343-9.
    View in: PubMed
    Score: 0.015
  14. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother. 1994 Oct; 38(10):2351-6.
    View in: PubMed
    Score: 0.007
  15. Dose ranging and fractionation of intravenous ciprofloxacin against Pseudomonas aeruginosa and Staphylococcus aureus in an in vitro model of infection. Antimicrob Agents Chemother. 1993 Sep; 37(9):1756-63.
    View in: PubMed
    Score: 0.007
  16. Efficacy of standard disc-diffusion test as applied to susceptibility of Staphylococcus aureus to tetracycline and minocycline. J Lab Clin Med. 1972 Feb; 79(2):316-25.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.